Halozyme Therapeutics (HALO) Amortizatization of Intangibles (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Amortizatization of Intangibles data on file, last reported at $2.2 million in Q1 2026.

• Amortizatization of Intangibles for Q1 2026 came in at $2.2 million, down 87.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.9 million (down 31.32% YoY), and the FY2025 annual result was $3.3 million, down 55.16% from the prior year.
• Amortizatization of Intangibles climbed to $2.2 million in Q1 2026 per HALO's latest filing, from $96000.0 in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $27.2 million in Q3 2022 and troughed at -$30.8 million in Q4 2022.
• A 5-year average of $10.0 million and a median of $17.8 million in 2024 frame the typical range for Amortizatization of Intangibles.
• The sharpest annual moves came in 2022 and 2024: Amortizatization of Intangibles plunged 1262.74% in 2022, then soared 868.01% in 2024.
• A 5-year view of Amortizatization of Intangibles shows it stood at -$30.8 million in 2022, then jumped by 105.94% to $1.8 million in 2023, then climbed by 0.88% to $1.8 million in 2024, then plunged by 94.79% to $96000.0 in 2025, then soared by 2238.54% to $2.2 million in 2026.
• Business Quant data shows HALO's Amortizatization of Intangibles at $2.2 million in Q1 2026, $96000.0 in Q4 2025, and $17.8 million in Q3 2025.